Royal Sense
Close ·
- P/E
- 45.13
Key Fundamentals
SMEHealthcare Equipment & SuppliesHealthcarePrice-based figures at the close · TTM
- ROCE
- 26.10%
- Debt to Equity
- 0.33
- EPS (TTM)
- ₹1.50
- Book Value
- ₹71.06
- Market Cap
- —
- P/E (TTM)
- 45.13
- P/B
- 0.95
- ROE
- 21.00%
- Dividend Yield
- 0.00%
- EBITDA
- ₹11.10 Cr
- 52W High
- ₹255.90
- 52W Low
- ₹65.95
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 95/100
Category scores
- Quality
- 33
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 25
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 97
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 48
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 3
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.95 times its book value
Weaknesses
1- Though the company is reporting repeated profits, it is not paying out dividend
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 5 | 3 |
| Oscillators | Bullish | 1 | 5 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 36.56
- Neutral
- MACD (12,26,9)
- −5.38
- Bullish
- SMA (50)
- 86.53
- Bearish
- SMA (200)
- 136.08
- Bearish
As of
Growth Rate
From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 1Y | +66.13% |
|---|
Net profit
| 1Y | +16.67% |
|---|
Operating cash flow
| 1Y | Turned negative |
|---|
Operating margin· change in pp
| 1Y | −3.84 pp |
|---|
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2024 | ₹18.00 Cr |
|---|---|
| Mar 2025 | ₹62.00 Cr |
| Mar 2026 | ₹103 Cr |
Net profit by year
| Mar 2024 | ₹2.00 Cr |
|---|---|
| Mar 2025 | ₹6.00 Cr |
| Mar 2026 | ₹7.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 11 | 22 | 40 | 43 | 60 |
| Expenses | 6 | 19 | 34 | 38 | 55 |
| Operating Profit | 5 | 3 | 6 | 6 | 5 |
| OPM % | 48% | 14% | 14% | 13% | 9% |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| PBT | 5 | 3 | 6 | 5 | 5 |
| Tax % | 7% | 25% | 29% | 25% | 32% |
| Net Profit | 5 | 2 | 4 | 4 | 3 |
| EPS (₹) | 9.94 | 4.86 | 7.97 | 7.59 | 5.79 |
Profit & Loss
₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 18 | 62 | 103 |
| Expenses | 16 | 53 | 92 |
| Operating Profit | 2 | 9 | 11 |
| OPM % | 13% | 14% | 11% |
| Other Income | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 |
| PBT | 2 | 9 | 10 |
| Tax % | 28% | 27% | 28% |
| Net Profit | 2 | 6 | 7 |
| EPS (₹) | 3.24 | 12.74 | 13.36 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 |
| Borrowings | 2 | 3 | 13 |
| Other Liabilities | 1 | 5 | 8 |
| Total Liabilities | 21 | 36 | 61 |
| Fixed Assets | 0 | 2 | 2 |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets | 20 | 33 | 59 |
| Total Assets | 21 | 36 | 61 |
Cash Flow
₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | −4 | 1 | −13 |
| Investing | −1 | −2 | 0 |
| Financing | 13 | 3 | 5 |
| Net Cash Flow | 9 | 2 | −8 |
| Free Cash Flow | −4 | 0 | −14 |
| CFO/EBITDA | −144 | 21 | −110 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Cash Conversion Cycle | 66 | 86 | 101 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | — | 35% | 26% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Royal Sense insights
52 extracted metrics across FY24–FY26.
Documents
- General announcements 5 Oct 2026
Frequently Asked Questions about Royal Sense
What does Royal Sense Ltd do?
Where is Royal Sense Ltd (ROYAL) listed?
Which sector does Royal Sense Ltd belong to?
What is the PE ratio of Royal Sense Ltd?
What is the 52-week high and low of Royal Sense Ltd?
What is the Return on Equity (ROE) of Royal Sense Ltd?
Company Information
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544143.md for Royal Sense Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.